The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Quadrivalent Vaccine against Human Papillomavirus to Prevent High-Grade Cervical Lesions
Open accessAbstract
BACKGROUND: Human papillomavirus types 16 (HPV-16) and 18 (HPV-18) cause approximately 70% of cervical cancers worldwide. A phase 3 trial was conducted to evaluate a quadrivalent vaccine against HPV types 6, 11, 16, and 18 (HPV-6/11/16/18) for the prevention of high-grade cervical lesions associated with HPV-16 and HPV-18. METHODS: In this randomized, double-blind trial, we assigned 12,167 women between the ages of 15 and 26 years to receive three doses of either HPV-6/11/16/18 vaccine or placebo, administered at day 1, month 2, and month 6. The primary analysis was performed for a per-protocol susceptible population that included 5305 women in the vaccine group and 5260 in the placebo group who had no virologic evidence of infection with HPV-16 or HPV-18 through 1 month after the third dose (month 7). The primary composite end point was cervical intraepithelial neoplasia grade 2 or 3, adenocarcinoma in situ, or cervical cancer related to HPV-16 or HPV-18. RESULTS: Subjects were followed for an average of 3 years after receiving the first dose of vaccine or placebo. Vaccine efficacy for the prevention of the primary composite end point was 98% (95.89% confidence interval [CI], 86 to 100) in the per-protocol susceptible population and 44% (95% CI, 26 to 58) in an intention-to-treat population of all women who had undergone randomization (those with or without previous infection). The estimated vaccine efficacy against all high-grade cervical lesions, regardless of causal HPV type, in this intention-to-treat population was 17% (95% CI, 1 to 31). CONCLUSIONS: In young women who had not been previously infected with HPV-16 or HPV-18, those in the vaccine group had a significantly lower occurrence of high-grade cervical intraepithelial neoplasia related to HPV-16 or HPV-18 than did those in the placebo group. (ClinicalTrials.gov number, NCT00092534 [ClinicalTrials.gov].).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Epidemiologic classification of human papillomavirus types associated with cervical cancer
Muñoz, N., Bosch, F. X., de Sanjosé, S., Herrero, R., Castellsagué, X., Shah, K. V., Snijders, P. J. F., & Meijer, C. J. L. M. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021641 · Cited by 6,249
Pathology and Genetics of Tumours of the Breast and Female Genital Organs
Tavassoli, F. A., & Devilee, P. (2003) · International Agency for Research on Cancer eBooks · Cited by 2,800
Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases
Garland, S. M., Hernandez-Avila, M., Wheeler, C. M., Perez, G., Harper, D. M., Leodolter, S., Tang, G. W. K., Ferris, D. G., Steben, M., Bryan, J., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa061760 · Cited by 1,886
Harper, D. M., Franco, E. L., Wheeler, C., Ferris, D. G., Jenkins, D., Schuind, A., Zahaf, T., Innis, B., Naud, P., De Carvalho, N. S., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17398-4 · Cited by 1,643
Harper, D. M., Franco, E. L., Wheeler, C. M., Moscicki, A.-B., Romanowski, B., Roteli-Martins, C. M., Jenkins, D., Schuind, A., Costa Clemens, S. A., & Dubin, G. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68439-0 · Cited by 1,632
Globocan 2000 : cancer incidence, mortality and prevalence worldwide
Ferlay, J., Pisani, P., & Parkin, D. M. (2001) · Medical Entomology and Zoology · Cited by 1,579
Villa, L. L., Costa, R. L., Petta, C. A., Andrade, R. P., Ault, K. A., Giuliano, A. R., Wheeler, C. M., Koutsky, L. A., Malm, C., Lehtinen, M., et al. (2005) · The Lancet Oncology · doi:10.1016/s1470-2045(05)70101-7 · Cited by 1,579
2001 Consensus Guidelines for the Management of Women With Cervical Cytological Abnormalities
Wright, Jr. (2002) · JAMA · doi:10.1001/jama.287.16.2120 · Cited by 1,215
Benedet, J. L. (2000) · International Journal of Gynecology & Obstetrics · doi:10.1016/s0020-7292(00)00300-3 · Cited by 1,104
Koutsky, L. A., Holmes, K. K., Critchlow, C. W., Stevens, C. E., Paavonen, J., Beckmann, A. M., DeRouen, T. A., Galloway, D. A., Vernon, D., & Kiviat, N. B. (1992) · New England Journal of Medicine · doi:10.1056/nejm199210293271804 · Cited by 943
Cited by
Human papillomavirus and cervical cancer
Schiffman, M., Castle, P. E., Jeronimo, J., Rodriguez, A. C., & Wacholder, S. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61416-0 · Cited by 2,985
Human papillomavirus and cervical cancer
Burd, E. M. (2003) · Clinical Microbiology Reviews · doi:10.1128/cmr.16.1.1-17.2003 · Cited by 2,420
Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases
Garland, S. M., Hernandez-Avila, M., Wheeler, C. M., Perez, G., Harper, D. M., Leodolter, S., Tang, G. W. K., Ferris, D. G., Steben, M., Bryan, J., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa061760 · Cited by 1,886
Correlates of protection induced by vaccination
Plotkin, S. A. (2010) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00131-10 · Cited by 1,745
HPV Vaccination and the Risk of Invasive Cervical Cancer
Lei, J., Ploner, A., Elfström, K. M., Wang, J., Roth, A., Fang, F., Sundström, K., Dillner, J., & Sparén, P. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1917338 · Cited by 1,487
A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women
Joura, E. A., Giuliano, A. R., Iversen, O.-E., Bouchard, C., Mao, C., Mehlsen, J., Moreira, E. D., Ngan, Y., Petersen, L. K., Lazcano-Ponce, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1405044 · Cited by 1,433
Saslow, D., Solomon, D., Lawson, H. W., Killackey, M., Kulasingam, S. L., Cain, J., Garcia, F. A. R., Moriarty, A. T., Waxman, A. G., Wilbur, D. C., et al. (2012) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21139 · Cited by 1,390
Human papillomavirus and cervical cancer
Crosbie, E. J., Einstein, M. H., Franceschi, S., & Kitchener, H. C. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60022-7 · Cited by 1,171
Cervical cancer: A global health crisis
Small, W., Bacon, M. A., Bajaj, A., Chuang, L. T., Fisher, B. J., Harkenrider, M. M., Jhingran, A., Kitchener, H. C., Mileshkin, L. R., Viswanathan, A. N., et al. (2017) · Cancer · doi:10.1002/cncr.30667 · Cited by 1,168
Efficacy of Quadrivalent HPV Vaccine against HPV Infection and Disease in Males
Giuliano, A. R., Palefsky, J. M., Goldstone, S., Moreira, E. D., Penny, M. E., Aranda, C., Vardas, E., Moi, H., Jessen, H., Hillman, R., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa0909537 · Cited by 1,146
Worldwide burden of cervical cancer in 2008
Arbyn, M., Castellsagué, X., de Sanjosé, S., Bruni, L., Saraiya, M., Bray, F., & Ferlay, J. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr015 · Cited by 1,130
Human Papillomavirus DNA versus Papanicolaou Screening Tests for Cervical Cancer
Mayrand, M.-H., Duarte-Franco, E., Rodrigues, I., Walter, S. D., Hanley, J., Ferenczy, A., Ratnam, S., Coutlée, F., & Franco, E. L. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa071430 · Cited by 1,100
Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Marth, C., Landoni, F., Mahner, S., McCormack, M., Gonzalez-Martin, A., & Colombo, N. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx220 · Cited by 1,073
Jemal, A., Simard, E. P., Dorell, C., Noone, A.-M., Markowitz, L. E., Kohler, B., Eheman, C., Saraiya, M., Bandi, P., Saslow, D., et al. (2013) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djs491 · Cited by 993
HPV Vaccine against Anal HPV Infection and Anal Intraepithelial Neoplasia
Palefsky, J. M., Giuliano, A. R., Goldstone, S., Moreira, E. D., Aranda, C., Jessen, H., Hillman, R., Ferris, D., Coutlee, F., Stoler, M. H., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1010971 · Cited by 948
Saslow, D., Solomon, D., Lawson, H. W., Killackey, M., Kulasingam, S. L., Cain, J. M., Garcia, F. A. R., Moriarty, A. T., Waxman, A. G., Wilbur, D. C., et al. (2012) · Journal of Lower Genital Tract Disease · doi:10.1097/lgt.0b013e31824ca9d5 · Cited by 915
Saslow, D., Solomon, D., Lawson, H. W., Killackey, M., Kulasingam, S. L., Cain, J., Garcia, F. A. R., Moriarty, A. T., Waxman, A. G., Wilbur, D. C., et al. (2012) · American Journal of Clinical Pathology · doi:10.1309/ajcptgd94evrsjcg · Cited by 791
A review of clinical trials of human papillomavirus prophylactic vaccines
Schiller, J. T., Castellsagué, X., & Garland, S. M. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.04.108 · Cited by 747
Cancers with increasing incidence trends in the United States: 1999 through 2008
Simard, E. P., Ward, E. M., Siegel, R., & Jemal, A. (2012) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20141 · Cited by 724
Lehtinen, M., Paavonen, J., Wheeler, C. M., Jaisamrarn, U., Garland, S. M., Castellsagué, X., Skinner, S. R., Apter, D., Naud, P., Salmerón, J., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70286-8 · Cited by 704
Hildesheim, A., Herrero, R., Wacholder, S., Rodriguez, A. C., Solomon, D., Bratti, M. C., Schiller, J. T., Gonzalez, P., Dubin, G., Porras, C., et al. (2007) · JAMA · doi:10.1001/jama.298.7.743 · Cited by 666
Canfell, K., Kim, J. J., Brisson, M., Keane, A., Simms, K. T., Caruana, M., Burger, E. A., Martin, D., Nguyen, D. T. N., Bénard, É., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30157-4 · Cited by 650
Brown, D. R., Kjaer, S. K., Sigurdsson, K., Iversen, O., Hernandez‐Avila, M., Wheeler, C. M., Perez, G., Koutsky, L. A., Tay, E. H., Garcia, P., et al. (2009) · The Journal of Infectious Diseases · doi:10.1086/597307 · Cited by 627
Arbyn, M., Xu, L., Simoens, C., & Martin-Hirsch, P. P. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009069.pub3 · Cited by 621
Dougan, M., & Dranoff, G. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132544 · Cited by 607
Peptide-based synthetic vaccines
Skwarczynski, M., & Toth, I. (2016) · Chemical Science · doi:10.1039/c5sc03892h · Cited by 596
Ault, K. A. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60852-6 · Cited by 590
The natural history of human papillomavirus infection
de Sanjosé, S., Brotons, M., & Pavón, M. A. (2018) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2017.08.015 · Cited by 589
Kushnir, N., Streatfield, S. J., & Yusibov, V. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.10.083 · Cited by 587
Immune responses to human papillomavirus
Stanley, M. (2006) · Vaccine · doi:10.1016/j.vaccine.2005.09.002 · Cited by 586
Joura, E. A., Leodolter, S., Hernandez-Avila, M., Wheeler, C. M., Perez, G., Koutsky, L. A., Garland, S. M., Harper, D. M., Tang, G. W., Ferris, D. G., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60777-6 · Cited by 581
Muñoz, N., Kjaer, S. K., Sigurdsson, K., Iversen, O.-E., Hernandez-Avila, M., Wheeler, C. M., Perez, G., Brown, D. R., Koutsky, L. A., Tay, E. H., et al. (2010) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djp534 · Cited by 566
Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape
Emens, L. A., Ascierto, P. A., Darcy, P. K., Demaria, S., Eggermont, A. M. M., Redmond, W. L., Seliger, B., & Marincola, F. M. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.01.035 · Cited by 566
Cervical cancer in low and middle‑income countries (Review)
Hull, R., Mbele, M., Makhafola, T., Hicks, C., Wang, S., Reis, R., Mehrotra, R., Mkhize‑Kwitshana, Z., Kibiki, G., Bates, D., et al. (2020) · Oncology Letters · doi:10.3892/ol.2020.11754 · Cited by 544
Garland, S. M., Steben, M., Sings, H. L., James, M., Lu, S., Railkar, R., Barr, E., Haupt, R. M., & Joura, E. A. (2009) · The Journal of Infectious Diseases · doi:10.1086/597071 · Cited by 532
Dayyani, F., Etzel, C. J., Liu, M., Ho, C.-H., Lippman, S. M., & Tsao, A. S. (2010) · Head & Neck Oncology · doi:10.1186/1758-3284-2-15 · Cited by 529
Markowitz, L. E., Hariri, S., Lin, C., Dunne, E. F., Steinau, M., McQuillan, G., & Unger, E. R. (2013) · The Journal of Infectious Diseases · doi:10.1093/infdis/jit192 · Cited by 521
HPV prophylactic vaccines and the potential prevention of noncervical cancers in both men and women
Gillison, M. L., Chaturvedi, A. K., & Lowy, D. R. (2008) · Cancer · doi:10.1002/cncr.23764 · Cited by 517
Rijkaart, D. C., Berkhof, J., Rozendaal, L., van Kemenade, F. J., Bulkmans, N. W., Heideman, D. A., Kenter, G. G., Cuzick, J., Snijders, P. J., & Meijer, C. J. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70296-0 · Cited by 515
Targeting Proteins for Destruction by the Ubiquitin System: Implications for Human Pathobiology
Schwartz, A. L., & Ciechanover, A. (2009) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.051208.165340 · Cited by 492
Cancer immunotherapies: advances and bottlenecks
Rui, R., Zhou, L., & He, S. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1212476 · Cited by 484
Muñoz, N., Manalastas, R., Pitisuttithum, P., Tresukosol, D., Monsonego, J., Ault, K., Clavel, C., Luna, J., Myers, E., Hood, S., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60691-7 · Cited by 478
Predictors of HPV vaccine uptake among women aged 19–26: Importance of a physician's recommendation
Rosenthal, S. L., Weiss, T. W., Zimet, G. D., Ma, L., Good, M. B., & Vichnin, M. D. (2011) · Vaccine · doi:10.1016/j.vaccine.2009.12.063 · Cited by 458
Gerend, M. A., & Shepherd, J. E. (2012) · Annals of Behavioral Medicine · doi:10.1007/s12160-012-9366-5 · Cited by 455
The FUTURE I/II Study Group (2010) · BMJ · doi:10.1136/bmj.c3493 · Cited by 415
Updating the Natural History of Human Papillomavirus and Anogenital Cancers
Moscicki, A.-B., Schiffman, M., Burchell, A., Albero, G., Giuliano, A. R., Goodman, M. T., Kjaer, S. K., & Palefsky, J. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.05.089 · Cited by 413
Prevalence of HPV After Introduction of the Vaccination Program in the United States
Markowitz, L. E., Liu, G., Hariri, S., Steinau, M., Dunne, E. F., & Unger, E. R. (2016) · Pediatrics · doi:10.1542/peds.2015-1968 · Cited by 383
Age-Specific Prevalence of Infection with Human Papillomavirus in Females: A Global Review
Smith, J. S., Melendy, A., Rana, R. K., & Pimenta, J. M. (2008) · Journal of Adolescent Health · doi:10.1016/j.jadohealth.2008.07.009 · Cited by 377
NCCN Guidelines Insights: Head and Neck Cancers, Version 2.2017
Adelstein, D., Gillison, M. L., Pfister, D. G., Spencer, S., Adkins, D., Brizel, D. M., Burtness, B., Busse, P. M., Caudell, J. J., Cmelak, A. J., et al. (2017) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.0101 · Cited by 371
Health and Economic Implications of HPV Vaccination in the United States
Kim, J. J., & Goldie, S. J. (2008) · New England Journal of Medicine · doi:10.1056/nejmsa0707052 · Cited by 365
Beyond Cervical Cancer: Burden of Other HPV-Related Cancers Among Men and Women
Chaturvedi, A. K. (2010) · Journal of Adolescent Health · doi:10.1016/j.jadohealth.2010.01.016 · Cited by 361
Human papillomavirus vaccines: WHO position paper
WHO (2009) · Biologicals · doi:10.1016/j.biologicals.2009.04.005 · Cited by 357
Introducing HPV Vaccine in Developing Countries — Key Challenges and Issues
Agosti, J. M., & Goldie, S. J. (2007) · New England Journal of Medicine · doi:10.1056/nejmp078053 · Cited by 350
Castellsagué, X., Muñoz, N., Pitisuttithum, P., Ferris, D., Monsonego, J., Ault, K., Luna, J., Myers, E., Mallary, S., Bautista, O. M., et al. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.185 · Cited by 347
An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results
Schiller, J. T., Castellsagué, X., Villa, L. L., & Hildesheim, A. (2008) · Vaccine · doi:10.1016/j.vaccine.2008.06.002 · Cited by 334
Quadrivalent Human Papillomavirus Vaccine
Gellin, B., Modlin, J. F., Barr, E., & Tamms, G. (2007) · Clinical Infectious Diseases · doi:10.1086/520654 · Cited by 330
Chaturvedi, A. K., Katki, H. A., Hildesheim, A., Rodríguez, A. C., Quint, W., Schiffman, M., Van Doorn, L.-J., Porras, C., Wacholder, S., Gonzalez, P., et al. (2011) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiq139 · Cited by 329
Human Papillomavirus Vaccines: An Updated Review
Cheng, L., Wang, Y., & Du, J. (2020) · Vaccines · doi:10.3390/vaccines8030391 · Cited by 329
Kjaer, S. K., Sigurdsson, K., Iversen, O.-E., Hernandez-Avila, M., Wheeler, C. M., Perez, G., Brown, D. R., Koutsky, L. A., Tay, E. H., García, P., et al. (2009) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-09-0031 · Cited by 328
Kreimer, A. R., Rodriguez, A. C., Hildesheim, A., Herrero, R., Porras, C., Schiffman, M., González, P., Solomon, D., Jiménez, S., Schiller, J. T., et al. (2011) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djr319 · Cited by 324
Joura, E. A., Garland, S. M., Paavonen, J., Ferris, D. G., Perez, G., Ault, K. A., Huh, W. K., Sings, H. L., James, M. K., Haupt, R. M., et al. (2012) · BMJ · doi:10.1136/bmj.e1401 · Cited by 316
Kenter, G. G., Welters, M. J. P., Valentijn, A. R. P. M., Löwik, M. J. G., Berends-van der Meer, D. M. A., Vloon, A. P. G., Drijfhout, J. W., Wafelman, A. R., Oostendorp, J., Fleuren, G. J., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1881 · Cited by 315
Kreimer, A. R., Struyf, F., Del Rosario-Raymundo, M. R., Hildesheim, A., Skinner, S. R., Wacholder, S., Garland, S. M., Herrero, R., David, M.-P., & Wheeler, C. M. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00047-9 · Cited by 306
Risk factors for and prevention of human papillomaviruses (HPV), genital warts and cervical cancer
Chelimo, C., Wouldes, T. A., Cameron, L. D., & Elwood, J. M. (2013) · Journal of Infection · doi:10.1016/j.jinf.2012.10.024 · Cited by 303
Settle, K., Posner, M. R., Schumaker, L. M., Tan, M., Suntharalingam, M., Goloubeva, O., Strome, S. E., Haddad, R. I., Patel, S. S., Cambell, E. V., et al. (2009) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-09-0149 · Cited by 296
Cervical cancer prevention: New tools and old barriers
Scarinci, I. C., Garcia, F. A. R., Kobetz, E., Partridge, E. E., Brandt, H. M., Bell, M. C., Dignan, M., Ma, G. X., Daye, J. L., & Castle, P. E. (2010) · Cancer · doi:10.1002/cncr.25065 · Cited by 293
Understanding and learning from the success of prophylactic human papillomavirus vaccines
Schiller, J. T., & Lowy, D. R. (2012) · Nature Reviews Microbiology · doi:10.1038/nrmicro2872 · Cited by 293
Goldhaber-Fiebert, J. D., Stout, N. K., Salomon, J. A., Kuntz, K. M., & Goldie, S. J. (2008) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn019 · Cited by 286
Lu, B., Kumar, A., Castellsagué, X., & Giuliano, A. R. (2011) · BMC Infectious Diseases · doi:10.1186/1471-2334-11-13 · Cited by 283
Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study
Gertig, D. M., Brotherton, J. M., Budd, A. C., Drennan, K., Chappell, G., & Saville, A. M. (2013) · BMC Medicine · doi:10.1186/1741-7015-11-227 · Cited by 277
Economic evaluation of human papillomavirus vaccination in the United Kingdom
Jit, M., Choi, Y. H., & Edmunds, W. J. (2008) · BMJ · doi:10.1136/bmj.a769 · Cited by 273
Therapeutic cancer vaccines: Are we there yet?
Klebanoff, C. A., Acquavella, N., Yu, Z., & Restifo, N. P. (2011) · Immunological Reviews · doi:10.1111/j.1600-065x.2010.00979.x · Cited by 271
Fall in Human Papillomavirus Prevalence Following a National Vaccination Program
Tabrizi, S. N., Brotherton, J. M. L., Kaldor, J. M., Skinner, S. R., Cummins, E., Liu, B., Bateson, D., McNamee, K., Garefalakis, M., & Garland, S. M. (2012) · Journal of Infectious Diseases · doi:10.1093/infdis/jis590 · Cited by 264
Human Papillomavirus Vaccine Efficacy and Effectiveness against Cancer
Kamolratanakul, S., & Pitisuttithum, P. (2021) · Vaccines · doi:10.3390/vaccines9121413 · Cited by 263
Adelstein, D. J., Ridge, J. A., Gillison, M. L., Chaturvedi, A. K., D'Souza, G., Gravitt, P. E., Westra, W., Psyrri, A., Martin Kast, W., Koutsky, L. A., et al. (2009) · Head & Neck · doi:10.1002/hed.21269 · Cited by 261
Human papillomavirus molecular biology
Harden, M. E., & Munger, K. (2017) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2016.07.002 · Cited by 260
Di Mario, S., Basevi, V., Lopalco, P. L., Balduzzi, S., D’Amico, R., & Magrini, N. (2015) · Journal of Immunology Research · doi:10.1155/2015/435141 · Cited by 257
Denny, L., de Sanjose, S., Mutebi, M., Anderson, B. O., Kim, J., Jeronimo, J., Herrero, R., Yeates, K., Ginsburg, O., & Sankaranarayanan, R. (2017) · The Lancet · doi:10.1016/s0140-6736(16)31795-0 · Cited by 246
Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries
Goldie, S. J., O'Shea, M., Campos, N. G., Diaz, M., Sweet, S., & Kim, S.-Y. (2008) · Vaccine · doi:10.1016/j.vaccine.2008.04.053 · Cited by 197
Kim, J. J., Andres-Beck, B., & Goldie, S. J. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6604023 · Cited by 156
Van de Velde, N., Boily, M.-C., Drolet, M., Franco, E. L., Mayrand, M.-H., Kliewer, E. V., Coutlée, F., Laprise, J.-F., Malagón, T., & Brisson, M. (2012) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djs395 · Cited by 140
Fesenfeld, M., Hutubessy, R., & Jit, M. (2013) · Vaccine · doi:10.1016/j.vaccine.2013.06.060 · Cited by 123
Integrating clinical, community, and policy perspectives on human papillomavirus vaccination
Fernández, M. E., Allen, J. D., Mistry, R., & Kahn, J. A. (2010) · Annual Review of Public Health · doi:10.1146/annurev.publhealth.012809.103609 · Cited by 97
Antibody Responses to SARS-CoV-2: Let’s Stick to Known Knowns
Baumgarth, N., Nikolich-Žugich, J., Lee, F. E.-H., & Bhattacharya, D. (2020) · The Journal of Immunology · doi:10.4049/jimmunol.2000839 · Cited by 84
Campos, N. G., Sharma, M., Clark, A., Lee, K., Geng, F., Regan, C., Kim, J., & Resch, S. (2017) · International Journal of Gynecology & Obstetrics · doi:10.1002/ijgo.12184 · Cited by 76
(2009) · PubMed · Cited by 70
Ferrer, R. A., Green, P. A., & Barrett, L. F. (2015) · Perspectives on Psychological Science · doi:10.1177/1745691615576755 · Cited by 58
Paz-Zulueta, M., Álvarez-Paredes, L., Rodríguez Díaz, J. C., Parás-Bravo, P., Andrada Becerra, M. E., Rodríguez Ingelmo, J. M., Ruiz García, M. M., Portilla, J., & Santibañez, M. (2018) · BMC Cancer · doi:10.1186/s12885-018-4033-2 · Cited by 58
The predicted impact of vaccination on human papillomavirus infections in Australia
Smith, M. A., Canfell, K., Brotherton, J. M. L., Lew, J., & Barnabas, R. V. (2008) · International Journal of Cancer · doi:10.1002/ijc.23633 · Cited by 54
Age-specific occurrence of HPV16- and HPV18-related cervical cancer
de Sanjose, S., Wheeler, C. M., Quint, W. G. V., Hunt, W. C., Joste, N. E., Alemany, L., Xavier Bosch, F., Myers, E. R., & Castle, P. E. (2013) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-13-0053 · Cited by 51
Todorovic, B., Hung, K., Massimi, P., Avvakumov, N., Dick, F. A., Shaw, G. S., Banks, L., & Mymryk, J. S. (2012) · Journal of Virology · doi:10.1128/jvi.01637-12 · Cited by 49
Yoshikawa, H., Ebihara, K., Tanaka, Y., & Noda, K. (2013) · Cancer Science · doi:10.1111/cas.12106 · Cited by 46
Cornall, A. M., Poljak, M., Garland, S. M., Phillips, S., Machalek, D. A., Tan, J. H., Quinn, M. A., & Tabrizi, S. N. (2017) · Papillomavirus Research · doi:10.1016/j.pvr.2017.10.002 · Cited by 22
See-and-Treat Approaches to Cervical Cancer Prevention for HIV-Infected Women
Chibwesha, C. J., & Cu-Uvin, S. (2011) · Current HIV/AIDS Reports · doi:10.1007/s11904-011-0084-6 · Cited by 9
Kukimoto, I., Matsumoto, K., Takahashi, F., Iwata, T., Tanaka, K., Yamaguchi-Naka, M., Yamamoto, K., Yahata, H., Nakabayashi, M., Kato, H., et al. (2020) · The Tohoku Journal of Experimental Medicine · doi:10.1620/tjem.251.287 · Cited by 8
Metadata
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-05-10
- Volume
- 356
- Issue
- 19
- Pages
- 1915-1927
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2127043059
- Cited by
- 2,055
- References
- 33
- FWCI
- 144.05
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.